uniQure (NASDAQ:QURE) Rating Reiterated by Cantor Fitzgerald

uniQure (NASDAQ:QURE)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $28.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 422.39% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the company. StockNews.com upgraded uniQure to a “sell” rating in a report on Monday, August 5th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of uniQure in a research report on Tuesday, August 20th. Finally, The Goldman Sachs Group increased their price objective on shares of uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.40.

uniQure Trading Down 5.5 %

QURE opened at $5.36 on Friday. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The firm has a 50-day moving average price of $6.76 and a two-hundred day moving average price of $5.64. The stock has a market capitalization of $260.22 million, a PE ratio of -0.86 and a beta of 0.95. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 1.06.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.08. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. The firm had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $3.47 million. As a group, equities analysts anticipate that uniQure will post -4.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Sectoral Asset Management Inc. acquired a new position in shares of uniQure in the 4th quarter valued at $1,981,000. Vanguard Group Inc. grew its stake in uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after acquiring an additional 109,740 shares during the period. Acadian Asset Management LLC increased its holdings in shares of uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after acquiring an additional 350,291 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of uniQure by 74.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock worth $818,000 after purchasing an additional 66,958 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth about $86,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.